Disc Medicine, Inc. (NASDAQ:IRON) Insider Rahul Khara Sells 7,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $55.54, for a total transaction of $416,550.00. Following the sale, the insider now owns 14,035 shares of the company’s stock, valued at $779,503.90. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rahul Khara also recently made the following trade(s):

• On Thursday, January 2nd, Rahul Khara sold 7,500 shares of Disc Medicine stock. The shares were sold at an average price of $62.75, for a total value of $470,625.00.

Disc Medicine Trading Down 1.2 %

IRON traded down $0.67 during trading hours on Tuesday, hitting $54.32. 225,512 shares of the company’s stock were exchanged, compared to its average volume of 461,864. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The firm has a market cap of $1.62 billion, a P/E ratio of -13.65 and a beta of 0.74. The firm has a 50 day moving average of $61.83 and a 200 day moving average of $54.23.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. As a group, research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

A number of hedge funds have recently bought and sold shares of IRON. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares in the last quarter. Quest Partners LLC purchased a new position in Disc Medicine in the third quarter worth approximately $131,000. Quantbot Technologies LP acquired a new position in Disc Medicine during the 3rd quarter worth approximately $146,000. Intech Investment Management LLC acquired a new position in Disc Medicine during the 3rd quarter worth approximately $228,000. Finally, SG Americas Securities LLC increased its position in shares of Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock valued at $239,000 after purchasing an additional 793 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on IRON. HC Wainwright restated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Wedbush restated an “outperform” rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $66.00 to $110.00 in a research report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Finally, Stifel Nicolaus upped their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $88.90.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.